Top Qs
Timeline
Chat
Perspective

SCH-50971

Pharmaceutical compound From Wikipedia, the free encyclopedia

SCH-50971
Remove ads

SCH-50971 is a histamine H3 receptor agonist which was under development for the treatment of anxiety disorders, gastrointestinal disorders, and migraine but was never marketed.[2][3]

Quick facts Clinical data, Other names ...

The drug acts as a potent, selective, and high-affinity agonist of the histamine H3 receptor.[4][5] It has negligible affinity for the histamine H1 receptor and other assessed receptors.[4] The drug is also not a histamine H2 receptor antagonist.[4] It has greatly improved selectivity compared to the earlier selective histamine H3 receptor agonist (R)-α-methylhistamine.[4][5] The drug is orally active and shows anti-allergy effects, antimigraine effects, sedative and hypnotic effects, and hypolocomotion in animals.[6][7][1] In terms of chemical structure, it is a cyclized pyrrolidine derivative of histamine.[8][4]

SCH-50971 was under development by Schering-Plough.[2] It reached the discovery or preclinical research stage of development.[3] The development of the drug was discontinued by 2001.[2] SCH-50971 was first described in the scientific literature by 1994.[9][10]

Remove ads

See also

References

Loading related searches...

Wikiwand - on

Seamless Wikipedia browsing. On steroids.

Remove ads